Winthrop Capital Management LLC Sells 1,013 Shares of Merck & Co., Inc. $MRK

Winthrop Capital Management LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,251 shares of the company’s stock after selling 1,013 shares during the quarter. Winthrop Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,049,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Legend Financial Advisors Inc. bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $25,000. CBIZ Investment Advisory Services LLC grew its holdings in Merck & Co., Inc. by 141.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after purchasing an additional 221 shares during the period. Mountain Hill Investment Partners Corp. purchased a new stake in Merck & Co., Inc. in the second quarter worth about $43,000. Advantage Trust Co increased its stake in shares of Merck & Co., Inc. by 57.1% during the second quarter. Advantage Trust Co now owns 550 shares of the company’s stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. Finally, Chung Wu Investment Group LLC bought a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $45,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $86.34 on Friday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $105.07. The company has a market capitalization of $214.30 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34. The firm has a 50 day moving average of $84.59 and a 200 day moving average of $82.06. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.36 by $0.22. The business had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company’s revenue was up 3.7% compared to the same quarter last year. During the same period last year, the business posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a report on Monday, November 3rd. Citigroup began coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $104.47.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 8,614 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the sale, the executive vice president directly owned 24,578 shares of the company’s stock, valued at $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.